This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Background
In 2014, the ACIP recommended routine use of PCV13 among adults aged ≥65 years.1 As per this recommendation, both PCV13 and PPSV23 should be routinely administered in series to all adults aged ≥65 years.1 The ACIP recommendations for the use of PCV13 (high-risk) in adults aged ≥50 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leak or cochlear implants remain unchanged.2
The ACIP recommendations were amended in 2015 to simplify the spacing between PCV13 and PPSV23 in adults aged >65 years.3 The recommendation states that the recommended interval for adults receiving PCV13 and PPSV23 is to be at least 1 year apart, regardless of sequence. In summary, this means that PCV13 is administered first, followed by PPSV23, with a gap of at least 1 year between the two. If an adult above 65 years of age received PPSV23, they will receive PCV13 after 1 year as the older recommendation. The recommended sequence and spacing of PCV13 and PPSV23 in adults aged >65 years is presented in the figure given below.3,4
Sequence and Spacing of PCV13 and PPSV23 in Adults Aged >65 Years3
Adapted from Kobayashi M, et al. 2015.
The ACIP 2019 guidelines recommend PCV13 for all adults aged ≥65 years based on shared clinical decision-making. This group includes those adults aged ≥65 years who do not have CSF leak, immunocompromising conditions or cochlear implant.4
When the vaccine providers and patients engage in shared clinical decision-making regarding the use of PCV13 vaccine in adults ≥65 years, they may consider to include the risk for pneumococcal disease for that person resulting from underlying medical conditions or the individual patient’s risk for exposure to PCV13 serotypes. The 2019 ACIP recommendations for the use of PCV13 and PPSV23 vaccines in adults aged 19 to 64 and ≥65 years are depicted in the table below.4
Conclusion
In summary, the ACIP recommends considering regularly offering PCV13 to:
Patients aged ≥65 years who have not previously received PCV13
Persons residing in nursing homes or other long-term care facilities
Persons residing in settings with low paediatric PCV13 uptake
Persons traveling to settings with no paediatric PCV13 programme
Patients aged ≥65 with chronic heart, lung or liver disease, diabetes or alcoholism, and those who smoke cigarettes or who have more than 1 chronic medical condition
According to the recent 2019 ACIP recommendations, shared clinical decision-making for PCV13 use for those persons aged ≥65 years is recommended, who have not received PCV13 previously and do not have CSF leak, immunocompromising condition or cochlear implant.4
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.